Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Total Current Liabilities (2020 - 2025)

HCW Biologics (HCWB) has disclosed Total Current Liabilities for 6 consecutive years, with $26.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 10.65% year-over-year to $26.9 million, compared with a TTM value of $26.9 million through Sep 2025, down 10.65%, and an annual FY2024 reading of $29.6 million, up 238.71% over the prior year.
  • Total Current Liabilities was $26.9 million for Q3 2025 at HCW Biologics, roughly flat from $26.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $30.1 million in Q3 2024 and bottomed at $1.1 million in Q2 2022.
  • Average Total Current Liabilities over 5 years is $12.1 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities plummeted 72.55% in 2022, then surged 455.01% in 2024.
  • Year by year, Total Current Liabilities stood at $2.3 million in 2021, then grew by 27.35% to $3.0 million in 2022, then skyrocketed by 195.88% to $8.7 million in 2023, then surged by 238.71% to $29.6 million in 2024, then decreased by 9.34% to $26.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for HCWB at $26.9 million in Q3 2025, $26.8 million in Q2 2025, and $27.1 million in Q1 2025.